.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF07_TenofovirDisoproxil.TenofovirDisoproxil .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF07_TenofovirDisoproxil.TenofovirDisoproxil| name: | TenofovirDisoproxil |
| ATC code: | J05AF07 | route: | oral |
| n-compartments | 1 |
Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NRTI) used as an antiretroviral medication for the treatment and prevention of HIV-1 infection and chronic hepatitis B. It is approved and widely used today as part of combination therapy regimens.
Pharmacokinetic parameters in healthy adults following single oral dose of tenofovir disoproxil 300 mg.
Eke, AC, et al., & Capparelli, EV (2021). Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02168-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318014
Burns, RN, et al., & Chaturvedula, A (2015). Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. Journal of clinical pharmacology 55(6) 629–638. DOI:10.1002/jcph.461 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25581815
Kearney, BP, et al., & Shah, J (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics 43(9) 595–612. DOI:10.2165/00003088-200443090-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15217303